Review patients with ATM to differentiate them from the patients with multiple sclerosis (MS) based on the criteria provided by the Transverse Myelitis Consortium Working Group. Also evaluate laboratory and clinical biomarkers. The gene discussed is ATM; the disease is myeloid sarcoma.